Form 4: Metsera Acquired by Pfizer; ARCH VCs Exit Holdings

ARCH Venture Partners entities and associated individuals reported the disposition of Metsera, Inc. common stock following its acquisition by Pfizer Inc. for $65.60 cash per share plus a CVR.

Summary

• Metsera, Inc. has been acquired by Pfizer Inc. through a merger with Mayfair Merger Sub, Inc., a wholly-owned subsidiary of Pfizer.
• At the effective time of the merger, each outstanding share of Metsera common stock was converted into the right to receive $65.60 in cash per share, plus one contractual contingent value right (CVR).
• The CVR represents the right to receive contingent payments in cash upon the achievement of certain specified milestones.
• ARCH Venture Fund XII, L.P. disposed of 18,503,128 shares of Metsera Common Stock.
• ARCH Venture Fund XIII, L.P. disposed of 8,313,680 shares of Metsera Common Stock.
• Following these transactions, ARCH Venture Fund XII, L.P. and ARCH Venture Fund XIII, L.P. beneficially own 0 shares directly.
• Several ARCH Venture Partners entities and individuals, including Keith Crandell, Steven Gillis, and Robert Nelsen, were identified as reporting persons, holding roles as Director and 10% Owner of Metsera, Inc.

Sentiment

Score: 7

Explanation: The sentiment is positive for the selling shareholders, including ARCH Venture Partners, as the merger provides a definitive cash exit at a specified price, along with potential future upside from CVRs. For the market, it signifies the successful completion of an M&A event, removing Metsera's stock from public trading.

Positives

• The merger provides a clear exit for Metsera shareholders, including ARCH Venture Partners, at a defined cash value of $65.60 per share.
• Shareholders also receive potential future upside through contingent value rights (CVRs) tied to milestone achievements.

Negatives

• Metsera, Inc. is no longer an independent publicly traded company, as it has become a wholly-owned subsidiary of Pfizer Inc.
• The value of the contingent value rights (CVRs) is uncertain and dependent on future events and milestone achievements.

Risks

• The contingent value rights (CVRs) are subject to the achievement of specific milestones, meaning there is no guarantee of additional payments beyond the initial cash consideration.
• The CVR agreement outlines terms and conditions that may affect the realization of contingent payments.

Future Outlook

Metsera, Inc. will operate as a wholly-owned subsidiary of Pfizer Inc. The future financial performance and strategic direction of Metsera will be integrated into Pfizer's operations. Contingent value rights (CVRs) offer potential future payments based on the achievement of specified milestones.

Industry Context

This acquisition exemplifies a common trend in the pharmaceutical and biotechnology sectors where larger, established companies like Pfizer acquire innovative smaller firms to expand their pipeline, technology, or market presence. Such mergers provide an exit strategy for venture capital investors and integrate promising assets into a broader corporate structure.

Comparison to Industry Standards

• The acquisition structure, combining an upfront cash payment with contingent value rights (CVRs), is a standard mechanism in biotech M&A. This approach helps bridge valuation gaps and aligns incentives for future performance, similar to deals seen with companies like Celgene (acquired by Bristol-Myers Squibb) or Allergan (acquired by AbbVie) where earn-outs or CVRs were part of the consideration.
• The $65.60 cash per share, combined with CVRs, represents a specific valuation for Metsera's assets and pipeline, which would be benchmarked against recent acquisitions of comparable clinical-stage or commercial-stage biotech companies based on their therapeutic areas, development progress, and market potential.

Management Changes

Corporate Governance

Related Party Transactions

• The reporting persons, including ARCH Venture Partners entities and associated individuals (Keith Crandell, Steven Gillis, Robert Nelsen), were directors and 10% owners of Metsera, Inc. The disposition of their beneficial ownership occurred as part of the merger transaction.

Stakeholder Impact

• Shareholders: Metsera shareholders received $65.60 cash per share and one CVR for each share, and their shares are no longer publicly traded.
• Employees: Metsera employees are now part of Pfizer Inc., potentially impacting their roles, benefits, and corporate culture.
• Pfizer Inc.: Gains Metsera's assets, intellectual property, and pipeline, enhancing its strategic capabilities.
• Regulatory Authorities: The transaction was subject to regulatory approvals, which have presumably been met for the merger to close.

Next Steps

• Integration of Metsera's operations and assets into Pfizer Inc.
• Monitoring and achievement of specified milestones for the contingent value rights (CVRs) to trigger potential future payments.

Key Dates

Keywords

Metsera, MTSR, Pfizer, Merger, Acquisition, ARCH Venture Partners, Form 4, Beneficial Ownership, Contingent Value Right, CVR, Biotech, Pharmaceutical